Pulmatrix Inc. (PULM)
undefined
undefined%
At close: undefined
5.75
-0.17%
After-hours Dec 13, 2024, 03:59 PM EST

Company Description

Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States.

The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.

It engages in developing Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma, and in patients with cystic fibrosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine.

The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc.

Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.

Pulmatrix Inc.
Pulmatrix Inc. logo
Country United States
IPO Date Mar 21, 2014
Industry Biotechnology
Sector Healthcare
Employees 22
CEO Peter Ludlum CMA, MBA

Contact Details

Address:
99 Hayden Avenue
Lexington, Massachusetts
United States
Website https://www.pulmatrix.com

Stock Details

Ticker Symbol PULM
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001574235
CUSIP Number 74584P301
ISIN Number US74584P3010
Employer ID 46-1821392
SIC Code 2834

Key Executives

Name Position
Peter Ludlum CMA, MBA Interim Chief Executive Officer
Dr. Alexander M. Klibanov Ph.D. Founder

Latest SEC Filings

Date Type Title
Nov 13, 2024 8-K Current Report
Nov 08, 2024 ARS Filing
Nov 08, 2024 DEF 14A Filing
Nov 08, 2024 10-Q Quarterly Report
Nov 08, 2024 8-K Current Report
Oct 08, 2024 8-K Current Report
Aug 13, 2024 10-Q Quarterly Report
Aug 13, 2024 8-K Current Report
Jul 19, 2024 8-K Current Report
May 29, 2024 8-K Current Report